LabVantage Announces New CEO
Mikael Hagstroem has been named as the company’s new CEO.
LabVantage Solutions, a laboratory informatics solutions and services provider, announced on March 25, 2021 that it has named Mikael Hagstroem as its new CEO.
Before taking on his new role, Hagstroem served as CEO and president at MetricStream, an independent provider of governance, risk, and compliance products and solutions; partner at McKinsey & Company and chief operating officer of McKinsey Analytics; and executive vice-president of the SAS Institute and president of SAS International, LabVantage said in a company press release. Additionally, Hagstroem is currently on the board of advisors of the Artificial Intelligence (AI) Forum and has served as chair of the World Economic Forum’s Global Agenda Council on Data-Driven Development, as a member of the executive committee of the US Council for International Business, and as an executive board member of the Atlantic Council.
“[Hagstroem] embodies the sense of purpose and passion required to tackle big goals and the expertise to achieve them,” said Purnendu Chatterjee, chairman of LabVantage Solutions, in the press release. “He is an accomplished business leader who has built innovative data-based enterprises across a range of industries. He is a visionary strategist who understands the transformational potential of advanced technologies and translates them into actionable business initiatives. An inspired leader, [Hagstroem] is committed to accelerating the use of new tools such as analytics and AI to address urgent global problems. We are thrilled to welcome him to LabVantage and excited at the prospect of what we can accomplish together.”
“LabVantage brings the Fourth Industrial Revolution–characterized as a range of new technologies that are fusing the physical, digital, and biological worlds and impacting all disciplines, economies, and industries–to the lab, and I am honored to take the helm,” Hagstroem added in the press release.
Source: LabVantage
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.
